Key Takeaways Madrigal gained conditional EU approval for Rezdiffra to treat adults with noncirrhotic MASH.The EU nod to Rezdiffra followed positive phase III MAESTRO-NASH data showing fibrosis and MASH benefits.Despite approval, MDGL stock fell as investors eyed competition from Novo Nordisk's Wegovy.Madrigal Pharmaceuticals (MDGL) announced that the European Commission (EC) has granted a conditional marketing authorization to Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic metabolic d ...